Martin Freed

Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts.

InteKrin Therapeutics, Inc. develops and commercializes therapeutics for metabolic and immune disorders. It develops therapeutics for diabetes, insulin resistance and multiple sclerosis. The company was founded by Dennis M. Lanfear and Christos S. Mantzoros in 2005 and is headquartered in Palo Alto, CA.

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA.

Vitae Pharmaceuticals LLC is a clinical-stage bio-pharmaceutical company, which engages in discovering and developing novel, small molecule drugs for diseases, including chronic kidney disease, diabetes and Alzheimer's disease, and autoimmune disorders, acute coronary syndrome, and immuno-oncology. The company was founded by John J. Baldwin, Bartosz A. Grzybowski, George M. Whitesides, and Eugene Shakhnovich on May 21, 2001 and is headquartered in Fort Washington, PA.

Avila Therapeutics, Inc. researches and develops covalent drugs. The company was founded in 2007 and is headquartered in Summit, NJ.

GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA.